SYGNIS AG

EANS-News: SYGNIS Pharma AG
SYGNIS announces six months results of fiscal year 2012

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
6-month report


Heidelberg (euro adhoc) - SYGNIS announces six months results of fiscal year
2012

Heidelberg, November  14,  2012  -  SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN
DE000A1E9B74; Prime Standard) today reports its financial results  for  the  six
months period ended September 30, 2012.

Financials


    - The net loss in the second quarter was EUR-1.3  million  
      (EUR-2.0  million  Q2 2011/2012). The net loss for the six months period 
      was EUR-2.5  million(EUR-3.3 million H1 2011/2012)
    - Total operating expenses for the  first  six  months  were  down  at  
      EUR 2.6 million (EUR4.3 million first half 2011/2012).
    - Cash including marketable  securities  amounted  to  EUR1.9  million  as  
      of September 30, 2012 (EUR8.1 million September 30, 2011).


Operational summary


    - In July 2012 SYGNIS implemented essential transaction steps as part of the
      necessary realignment. These steps included the signing of the Term  Sheet
      regarding the merger  with  X-Pol  Biotech  S.L.  (X-Pol)  and  the  early
      prolongation of the SEDA agreement.
    - Moreover SYGNIS was informed in September 2012 about  the  fact  that  the
      German  Federal  Financial  Supervisory  Authority  (BaFin)  has   granted
      Genetrix an  exemption  from  the  obligations  according  to  §  35  WpÜG
      (Securities Acquisition and Takeover Act),  in  particular  to  provide  a
      mandatory offer to  the  shareholders  of  SYGNIS.  This  exemption  is  a
      prerequisite for the successful implementation of the business combination
      with X-Pol.
    - The operating expenses and the liquidity  outflow  during  the  first  six
      months of the fiscal year were within the expectations of the Company.
    - Within the KIBRA project further progress has been achieved on the way  of
      identifying lead compounds. In addition the Company  has  intensified  the
      partnering process by numerous discussions with potential partners.



Significant events after the balance sheet date


    - In connection with the realignment of the Company, the  Board  member  Dr.
      Frank Rathgeb has resigned from the Management Board of SYGNIS  by  mutual
      agreement with the Supervisory Board on 31 October 2012.

    - Representing 73% of the voting share capital the  shareholders  of  SYGNIS
      agreed to all items of the agenda in the Annual Shareholder Meeting. These
      items primarily include the following measures:


      - Resolution on the reduction of the share capital of the Company from
         EUR 16,829,504 to EUR 2,103,688 by consolidating shares in a 8:1 ratio
      -  Capital increase against contribution in kind from  EUR  2,103,688  
         to  EUR 9,349,724 by contribution of all shares of X-Pol
      -  Election of the new Supervisory Board
      -  Change of fiscal year to the calendar year  and  constituting  a  
         short year from 1 April to 31 December 2012

    - Subsequently  to  the  Shareholders'  Meeting  on  17  October  2012  the
      Supervisory Board has appointed Mrs. Pilar de la Huerta to the  Management
      Board of the Company and has nominated her as CEO.




Outlook


    - For the upcoming months emphasis is being placed  on  securing  sufficient
      funding  and  the  realignment  of  the  Company  through   the   business
      combination with X-Pol.  With  the  marketing  of  the  DNA  amplification
      technologies and products, SYGNIS is aiming to generate  initial  revenues
      and to establish a profitable business in the medium term.
    - For the KIBRA project, the partnering process is ongoing. However,  should
      the Company not succeed in winning a partner  for  KIBRA,  the  Management
      Board will have to reconsider the future of this project.
    - The Company's available funds as of 30 September 2012 secure the liquidity
      of SYGNIS until approximately March 2013. To further finance its  business
      activities, the Company will have to rely on further  funding  from  March
      2013 on.






|Key financial figures for the second quarter of short fiscal year  |
|2012 ended September 30, 2012 and corresponding figures (IFRS)     |
|Numbers in million euros          |Q2 2012         |Q2 2011/2012    |
|Revenues                          |0.1             |0.0             |
|Total expenses                    |1.3             |2.1             |
|EBIT                              |-1.2            |-2.1            |
|Net results for the period        |-1.3            |-2.0            |
|Intangible assets                 |2.2             |20.5            |
|Liquidity at end of quarter       |1.9             |8.1             |
|Equity                            |3.5             |19.4            |
|(equity ratio in %)               |(60)            |(59)            |
|Long-term financial liabilities   |0.0             |8.0             |
|Operating Cash Flow               |-1.2            |-2.5            |



|Key figures for the first six months of short fiscal year 2012     |
|ended September 30, 2012 and comparables (IFRS)                    |
|Numbers in million euros          |H1 2012         |H1 2011/12      |
|Revenues                          |0.1             |0.2             |
|Total expenses                    |2.6             |4.3             |
|EBIT                              |-2.5            |-4.2            |
|Net results for the period        |-2.5            |-3.3            |
|Operating cash flow               |-2.5            |-4.5            |


The report on the first six months of the short fiscal year 2012 which ended  on
September 30, 2012 is available at the SYGNIS webpage at www.sygnis.de.



About SYGNIS Pharma AG: www.sygnis.de
SYGNIS  Pharma  AG  (Heidelberg,  Germany)  is  currently   a   specialty   drug
development company, focusing on innovative  treatments  for  underserved  human
diseases. Early in 2012 the company decided to discontinue  its  Phase  II  lead
program AX200 in stroke. While the company continued research activities in  the
field of cognitive disorders, it started at  the  same  time  a  systematic  M&A
process, to add new operational assets  and  activities  to  SYGNIS  Pharma  AG.
SYGNIS Pharma AG is  listed  in  the  Prime  Standard  of  the  Frankfurt  Stock
Exchange under the ticker: LIOK; and ISIN: DE000A1E9B74.


About X-Pol Biotech, S.L.: www.xpolbiotech.com
X-Pol Biotech, S.L. (Madrid, Spain) is a biotechnology company created by  Prof.

Luis Blanco and GENETRIX in 2008 with a focus on the development  of  tools  and
technologies for the DNA amplification and sequencing market. In  July  2012  X-
Pol has licensed its key product, an  improved  polymerase  for  amplifying  DNA
called "Qualiphi®" to Qiagen for its worldwide commercialisation.


For further information please contact:
                                                                                
                                                               |
|Peter Willinger                                                        |
|CFO                                                                            
                                                                  |
|SYGNIS Pharma AG |
|Tel.: +49 6221 454836                                                    
|E-mail: peter.willinger@sygnis.de                                           
                                    

### Disclaimer
Some statements included in this  press  release,  relating  neither  to  proven

financial results nor other  historical  data,  should  be  viewed  as  forward-
looking, i.e. not definite. Such statements are  mainly  predictions  of  future
results, trends, plans or goals. These statements should not  be  considered  to
be total guarantees since given their very nature they are subject to known  and
unknown risks and imponderability and can be affected  by  other  factors  as  a
consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG
may deviate greatly from the  established  conclusions  or  implied  predictions
contained in such statements. SYGNIS does not undertake to  publicly  update  or
revise these statements in the light of new information  or  future  results  or
for any other reason. ###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: